China Pharma Holdings (CPHI) Total Non-Current Liabilities (2010 - 2023)

China Pharma Holdings' Total Non-Current Liabilities history runs 11 years deep, the most recent figure standing at $10.5 million for Q1 2023.

• Quarterly Total Non-Current Liabilities changed N/A year-over-year to $10.5 million in Q1 2023, while the trailing twelve-month figure through Mar 2023 was $10.5 million (changed N/A YoY) and the FY2022 annual result came in at $11.1 million, down 24.71% from the prior year.
• Total Non-Current Liabilities was $10.5 million for Q1 2023 at China Pharma Holdings, down from $11.1 million in the prior quarter.
• Across five years, Total Non-Current Liabilities topped out at $14.7 million in Q4 2021 and bottomed at $9.6 million in Q3 2021.
• A 5-year average of $11.0 million and a median of $10.5 million in 2023 frame the typical range for Total Non-Current Liabilities.
• Annual changes were most pronounced in 2021 — Total Non-Current Liabilities jumped 42.28% — and 2022, when it fell 24.71%.
• China Pharma Holdings' Total Non-Current Liabilities stood at $10.6 million in 2019, then declined by 2.18% to $10.4 million in 2020, then soared by 42.28% to $14.7 million in 2021, then decreased by 24.71% to $11.1 million in 2022, then retreated by 5.3% to $10.5 million in 2023.
• Business Quant data shows CPHI's Total Non-Current Liabilities at $10.5 million in Q1 2023, $11.1 million in Q4 2022, and $14.7 million in Q4 2021.